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a  b  s  t  r  a  c  t
Severe  maternal  complications  in pregnancy  in  sub-Saharan  Africa  contribute  to  high  maternal  mortality
and  morbidity.  Incidence  data  on  severe  maternal  complications,  life-threatening  conditions,  maternal
deaths  and  birth  outcomes  are  essential  for clinical  audit  and  to inform  trial design  of the  types  and
frequency  of  expected  severe  adverse  events  (SAEs).  However,  such  data  are  very  limited,  especially  in
sub-Saharan  Africa.  We  set  up  standardized,  systematic  clinical  surveillance  embedded  into  routine  clin-
ical care  in  a rural  county  hospital  in Kenya.  Pregnant  women  and  newborns  are systematically  assessed
and  investigated.  Data  are  reported  using  a standardized  Maternal  Admission  Record  that  forms  both  the
hospital’s  clinical  record and  the  data  collection  tool.  Integrating  clinical  surveillance  with  routine  clinical
care  is  feasible  and  should  be expanded  in  sub-Saharan  Africa,  both  for  improving  clinical  practice  and
as a basis  for  intervention  studies  to  reduce  maternal  and  newborn  mortality  and morbidity  where  rates
are highest.
© 2015  The  Authors.  Published  by Elsevier  Ltd. This  is an open  access  article  under  the  CC BY  license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
The burden of maternal mortality in sub-Saharan Africa (sSA)
remains high. In Kenya, in 2013, the estimated maternal mortality
ratio (MMR)  was 277 (175–414) per 100,000 [1], which corre-
sponded to an estimated 4361 (2759–6514) maternal deaths [1]
across over 4700 health facilities [2].
Maternal deaths are the ‘tip of the iceberg’ of the 20–30 fold
more women who  experience severe maternal morbidity [3]. This
includes women with a “near miss” or life threatening complication
(signs of organ dysfunction as a result of a severe complication at
delivery) [4], severe maternal complications (severe post-partum
haemorrhage, severe pre-eclampsia, eclampsia, sepsis or severe
systemic infection, ruptured uterus, and severe complications of
termination of pregnancy) [5]. In addition, there are many less
severe conditions which impact on maternal health and wellbeing
and are not currently well-deﬁned or measured [3]. In a recent
systematic review, including facility based studies in Africa, life-
threatening conditions (LTCs) occurred in 0.4–0.8% of all deliveries
∗ Corresponding author at: KEMRI-Wellcome Trust Research Programme, PO Box
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[6], although accurate data were available from only three stud-
ies [7–9]. Severe maternal complications [4], ranged more widely:
from 0.6% to 15% of deliveries [6], based on limited data from
another three studies [10–12]. Less severe conditions are not usu-
ally reported at all, but tools to identify these in resource-poor
settings are proposed by the WHO  Maternal Morbidity Working
Group [3].
Improving health information systems [13], with clinical
surveillance and data collection at health facilities needs both polit-
ical and ﬁnancial support. Integrating clinical surveillance into
routine clinical care, and engagement and ownership of the system
by health facility staff can help reduce costs and ensure systems are
supported.
At present, the limited data make it difﬁcult to estimate the bur-
den of maternal mortality and morbidity, as well as past trends.
We  do not know whether variations in incidence are due to chance
(particularly for relatively rare events such as deaths), differences
in reporting (for example in deﬁnitions), or other factors, such as
ability to access care, variations in co-morbidities in the popula-
tion (such as HIV infection), and/or the clinical care available in the
health facility.
Structured medical records can support clinical care as an
“aide-memoire” of key clinical items and provide a standard-
ized framework for data collection. These data themselves then
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facilitate clinical audit to ensure standards of care are met. In
addition, the data provide a platform for research studies and can
inform the design and conduct of clinical trials. Background data on
maternal mortality and morbidity inform trial safety monitoring in
terms of expected frequencies of Severe Adverse Events (SAEs) and
Adverse Events (AEs) in phase II and III trials. Furthermore, if and
when vaccines given during pregnancy are rolled out, systems will
be needed for phase IV surveillance for events which may  or may
not be associated with vaccines.
This paper aims to describe the methods undertaken to achieve
systematic clinical surveillance in the maternity department of a
rural county hospital in Kenya, in close collaboration with hospital
management, and involving all hospital staff providing maternity
care. The purpose of the surveillance was to support clinical care,
ensure staff engagement and sustainability, inform clinical audit,
and provide a platform for research and inform future clinical trials.
2. Methods
Kiliﬁ County Hospital (KCH) is a government run county hospital
in rural Kenya, with around 4000 deliveries per year. KCH provides
comprehensive emergency obstetric and neonatal care, including:
intrapartum (e.g. instrumental deliveries (vacuum) and Caesarean
sections) and postpartum (e.g. removal of retained placentas and
products of conception) procedures; basic new-born resuscitation
when clinically indicated; blood transfusion, and basic care activi-
ties (e.g. administration of intravenous (IV) antibiotics, uterotonic
drugs (e.g. oxytocin), and IV anticonvulsants).
All mothers who present in labour are registered on admission
by ﬁeldworkers based in the maternity ward 24 h a day, seven days
a week. Clinical data are documented by government-employed
nurses who then complete a structured maternal admission record
(MAR). The form (see supplementary web annexe) was developed
and piloted with clinical staff, and there has been on-going devel-
opment with support from research staff, who are available on a
daily basis to discuss amendments and improvements. The MAR
includes antenatal history, delivery details, partogram (the national
standard) and maternal problems before discharge as well as new-
born outcomes. Examination is structured and includes routine
observations (respiratory rate, heart rate, temperature, blood pres-
sure) as well as symphyseal-fundal height, cervical assessment and
general examination. Investigations for clinical purposes that are
routinely taken on admission include a full blood count and two
point of care tests: a rapid test for malaria infection and a urine
dipstick for proteinuria and nitrites. Rapid HIV testing is offered if
the woman has not been tested in the current pregnancy, according
to national guidelines.
3. Results
Clinical surveillance is fully integrated into clinical care in the
KCH maternity department. Details of 16,728 maternal admissions
have been recorded from 1st January 2011 to 31st December 2014.
The numbers of annual maternal admissions have been increasing
(3651 in 2011 to 5572 in 2014), possibly in part because deliv-
ery fees ceased to be charged in 2013. Clinical assessment and
documentation are undertaken by nursing and medical staff as
part of routine care. Changes in nursing, medical staff and hospital
management have occurred, and been associated with transient
increases in missing data (between 1% and 18% of data points
are missing). However, once embedded, surveillance systems have
been integrated into care and maintained. The data from MARs have
facilitated regular discharge reports, clinical audits and provided a
platform for studies of precise rates of adverse events, which will
be submitted for publication. Recent and ongoing research studies
include studies of risk factors for adverse maternal and adverse
perinatal outcomes, the clinical and molecular epidemiology of
Group B Streptococcus, and INTERBIO-21st assessing the effects of
adverse intrauterine environment on foetal growth (http://www.
interbio21.org.uk/).
4. Discussion
Routine surveillance of maternal admissions for delivery can be
integrated into clinical care and sustained by becoming established
as the working ‘culture’. Data can be used to inform clinical practice
(through audit), as a platform for research studies, and as a rich data
source for maternal vaccine trials.
Maternal vaccines in development, such as those for Group B
Streptococcus [14] and respiratory syncytial virus (RSV) could sub-
stantially reduce the burden of maternal and neonatal infection,
building on the maternal tetanus vaccination programme in sSA
[15,16]. Maternal vaccination, however, presents special concerns
both for the safety of study participants [17], and for ongoing phase
IV monitoring if the vaccine is subsequently introduced. In other
settings, retrospective maternal data to establish safety have been
used as a comparison group, following vaccine introduction, for
example in the USA and the UK following the introduction of mater-
nal pertussis vaccination [18,19]. Surveillance systems in sSA are
inadequate to provide these data at present, despite the need for
interventions to be introduced safely and, if effective, at scale.
We have established a successful model for integrating stan-
dardized clinical surveillance with routine clinical care. It is needed
in more health facilities in sSA, both for clinical practice, for our
understanding of maternal health, and to inform and trial pre-
ventive methods to reduce the burden of maternal mortality and
morbidity where rates are highest.
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